Home / Our Companies / Cynaptec
Cynaptec Pharmaceuticals
Advancing novel psychedelic-derived therapeutics for neurological disorders
ABOUT CYNAPTEC
Transforming Treatment for Chronic Cluster Headache
Cynaptec Pharmaceuticals is a 64% owned subsidiary of Lobe Sciences focused on developing next-generation psychedelic-derived therapeutics. Our lead program, L-130 (Psilocin Mucate), is being developed for the treatment of chronic cluster headache—one of the most painful and underserved neurological conditions.
Cluster headache is often called “suicide headache” due to the extreme severity of pain. Current treatments offer limited relief, creating significant unmet medical need.
LEAD PROGRAM
L-130 (Psilocin Mucate)
Indication
Chronic Cluster Headache
Development Stage
Phase 1/2a
Molecule Type
Conjugated Psilocin
L-130 is a novel conjugated psilocin compound designed to provide improved pharmacokinetic properties compared to traditional psilocybin formulations. The compound offers potential advantages including more predictable dosing, improved tolerability, and reduced psychoactive side effects while maintaining therapeutic efficacy.
Explore Our Full Pipeline
Learn about all of our development programs across Lobe Sciences subsidiaries.